Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.51 |
| ▸ | RAB9A | P51151 | 9/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1163887 | 0.99 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL13238050 | 0.86 | RAB9A (0.48) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL13237921 | 0.84 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL13267338 | 0.84 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL5695242 | 0.83 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL13237912 | 0.83 | LCK (0.49) | GAA | |
| SCHEMBL5235840 | 0.82 | LCK (0.34) | NPC1RAB9ASMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL5695255 | 0.82 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL13237895 | 0.82 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL13237939 | 0.82 | LCK (0.51) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170872-B1 | PROCESS FOR THE PREPARATION OF THE N-(2-CHLORO-4-METHYL-3-THIENYL)-1H- BENZIMIDAZOL-2-AMINE HYDROCHLORIDE AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2010-09-01 | — | — | EP | claimed |
| EP-2170872-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | Sanofi-Aventis U.S. LLC (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009006066-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2009-01-08 | — | — | WO | claimed |
| WO-2011019784-A1 | PROCESS FOR PREPARING 2-CHLORO-3N-(2-BENZIMIDAZOLYL)-4-METHYL-3-THIENYLAMINE USEFUL AS A SODIUM/PROTON EXCHANGER TYPE 3 INHIBITOR | SANOFI-AVENTIS U.S. LLC (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011019784-A1 | PROCESS FOR PREPARING 2-CHLORO-3N-(2-BENZIMIDAZOLYL)-4-METHYL-3-THIENYLAMINE USEFUL AS A SODIUM/PROTON EXCHANGER TYPE 3 INHIBITOR | SANOFI-AVENTIS U.S. LLC (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011019680-A1 | PROCESS FOR PREPARING 4-METHYL-3-THIENYLAMINE HYDROCHLORIDE | SANOFI-AVENTIS U.S. LLC (US) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011019781-A1 | PROCESS FOR PREPARING 2-ARYLAMINO OR HETEROARYLAMINO SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | SANOFI-AVENTIS U.S. LLC (US) | 2011-02-17 | — | — | WO | disclosed |
| EP-2170872-B1 | PROCESS FOR THE PREPARATION OF THE N-(2-CHLORO-4-METHYL-3-THIENYL)-1H- BENZIMIDAZOL-2-AMINE HYDROCHLORIDE AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-2170872-B1 | PROCESS FOR THE PREPARATION OF THE N-(2-CHLORO-4-METHYL-3-THIENYL)-1H- BENZIMIDAZOL-2-AMINE HYDROCHLORIDE AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7763643-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7763643-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-20090137630-A1 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-7488746-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-02-10 | — | — | US | disclosed |
| US-7488746-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-02-10 | — | — | US | disclosed |
| WO-2009006066-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006066-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080070947-A1 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070947-A1 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-20 | — | — | US | disclosed |
| US-7317033-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| US-7317033-B2 | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137630-A1 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS | PLAT, CPS1, TST | NPC1 238/4885RAB9A 3901/4885SMN1; SMN2 691/4885 |
| US-20080070947-A1 | SUBSTITUTED THIOPHENES: COMPOSITIONS, PROCESSES OF MAKING, AND USES IN DISEASE TREATMENT AND DIAGNOSIS | PLAT, TST, PNLIP | NPC1 183/4885RAB9A 4313/4885SMN1; SMN2 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.